TABLE 3.
Overview of prevalence of cognitive change at different breast cancer treatment stages
| Treatment stage | Prevalence of cognitive change (total sum of patients) | Treatment group | Prevalence of cognitive change (total sum of patients per treatment group) | ||
|---|---|---|---|---|---|
| Improvement | Decline | Improvement | Decline | ||
| After treatment (T1) compared with baseline (T0) | 15% (527) | 24% (861) | CT | 18% (418) | 25% (713) |
| No‐CT | 11% (109) | 18% (148) | |||
| Controls | 12% (115) | 12% (171) | |||
| Short‐term FU (T2) compared with baseline (T0) | 14% (195) | 15% (319) | CT | 16% (155) | 14% (222) |
| No‐CT | 5% (40) | 15% (97) | |||
| Controls | – | – | |||
| Long‐term FU (T3) compared with baseline (T0) | 31% (128) | 24% (212) | CT | 32% (85) | 27% (169) |
| No‐CT | 30% (43) | 14% (43) | |||
| Controls | 17% (54) | 8% (103) | |||
Note: The “CT‐group” consists of patients indicated for chemotherapy and if necessary, radiotherapy and/or endocrine therapy. The “no‐CT group” consists of patients indicated for radiotherapy and/or endocrine therapy.
Abbreviations: CT, chemotherapy; long‐term FU, follow‐up of at least 1 year after treatment completion; short‐term FU, follow‐up of a maximum of 1 year after treatment completion; no‐CT, endocrine and/or radiotherapy.